Loading clinical trials...

ACTIVE_NOT_RECRUITINGPHASE2

Trial of JYB1904 in Patients With Allergic Asthma

Phase IIa Trial to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety of JYB1904 in Patients With Allergic Asthma

NCT06438757•Jemincare

View on ClinicalTrials.gov

Summary

This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Able to provide written informed consent voluntarily;
•Aged 18-75 years, weight ≥ 40 kg, male or female;
•Diagnosed Allergic asthma.

Exclusion Criteria

•Prior exposure to anti-IgE therapy within 1 year;
•Allergic to anti-IgE biologics;
•Current smokers, or quit smoking within 1 year;
•Combined with other non-allergic diseases that cause IgE elevation；
•History of malignancy, autoimmune diseases, Immune complex mediated diseases, Hypereosinophilic syndrome;
•Other conditions unsuitable for the trial judged by the investigator.

Locations (1)

Shanghai General Hospital

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

June 19, 2024

Primary Completion Date

October 31, 2025

Completion Date

October 31, 2025

Last Updated

May 7, 2025

Enrollment

ACTUAL participants

Conditions

Allergic Asthma

Interventions

JYB1904

DRUG

Omalizumab

DRUG

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

NCT05008965

Allergic Asthma

View study

RECRUITINGPHASE3

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

NCT04699604

Allergic Asthma

View study

ENROLLING_BY_INVITATIONEARLY_PHASE1

Asthma Inflammation Research

NCT01536522

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 7, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Trial of JYB1904 in Patients With Allergic Asthma

Inclusion Criteria

Exclusion Criteria

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

Asthma Inflammation Research

Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis

Tyrosine Allergoid Paediatric and Adult Study

Documentation of Efficacy of Intralymphatic Allergen Immunotherapy